Mylan is teaming up with California-based biotechnology firm Revance Therapeutics to develop and commercialise a biosimilar of Allergan’s world-renowned Botox (onabotulinumtoxinA) injection, as part of Mylan’s long-term strategy to bring to market complex products and biosimilars, as well as to gain traction in the growing global market for neuromodulators.
Mylan is teaming up with California-based biotechnology firm Revance Therapeutics to develop and commercialise a biosimilar of Allergan’s world-renowned Botox (onabotulinumtoxinA) injection, as part of Mylan’s long-term strategy to bring to market complex products and biosimilars, as well as to gain traction in the growing global market for neuromodulators.
Under the firms’ global collaboration and license agreement, Mylan and Revance plan to work together to gain regulatory approval in...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
